All In Biotech

Drug Trial Radar · NCT07743112

A Phase 2 Study of MAX-40279 Combined With Venetoclax and Azacitidine in Unfit Newly Diagnosed Acute Myeloid Leukemia

Last checked: Nov 19, 2026Latest source record: Aug 3, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

43

Planned (sponsor's estimate)

Start

Sep 5, 2025

Primary completion

Sep 1, 2027

Study completion Dec 1, 2027

Sponsor

Lead sponsor
Maxinovel Pty., Ltd.Industry
Sponsor type
Industry
First posted
Aug 3, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a prospective, multicenter, phase Ⅱ study consisting of dose escalation and ex-pansion stages in unfit newly diagnosed AML.

Conditions

  • Acute Myeloid Leukemia

Interventions

  • MAX-40279Drug

    Dose escalation:MAX-40279: 40 mg, 50 mg, and 60 mg twice daily (BID). Dose expantion: MAX-40279 RP2D. Venetoclax: 100 mg on day 1, 200 mg on day 2, and 400 mg daily thereafter. Azacitidine: 75 mg/m2 days 1-7. 28 days are one cycle.

  • AzacitidineDrug

    Given by IV, 75 mg/m2

  • VenetoclaxDrug

    100 mg on day 1, 200 mg on day 2, and 400 mg daily thereafter.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. DLTTime frame: Dose escalation; an average of 6 months.
  2. Adverse events (AEs), serious adverse events (SAEs)Time frame: Through study completion; an average of 24 months.
  3. Maximum Tolerated Dose (MTD) or Recommended Phase 2 Dose (RP2D)Time frame: Dose escalation; an average of 6 months.
  4. CRcTime frame: Through study completion; an average of 24 months.

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Institute of Institute of Hematology & Blood Diseases Hospital ( Chinese Academy of Medical Sciences)

    Tianjin, China · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.